Recent developments in the molecular characterization and treatment of oligodendroglial tumors.
暂无分享,去创建一个
M. J. van den Bent | J. Cairncross | O. Chinot | J Gregory Cairncross | Martin van den Bent | Olivier-Louis Chinot
[1] E. Newlands,et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. , 1996, European journal of cancer.
[2] Y. Shoshan,et al. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[4] B. Scheithauer,et al. Mixed oligoastrocytomas: a survival and prognostic factor analysis. , 1994, Neurosurgery.
[5] B. Fisher,et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Cairncross,et al. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. , 1989, Journal of neurosurgery.
[7] R. Hatlevoll,et al. Oligodendroglioma: incidence and biological behavior in a defined population. , 1985, Journal of neurosurgery.
[8] M. J. van den Bent,et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Markoe,et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. , 1997, International journal of radiation oncology, biology, physics.
[10] C. Kennard,et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.
[11] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[12] Susan M. Chang,et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Macdonald. Low-grade gliomas, mixed gliomas, and oligodendrogliomas. , 1994, Seminars in oncology.
[14] J. Cairncross,et al. Salvage chemotherapy for oligodendroglioma. , 1996 .
[15] van den Bent Mj,et al. Chemotherapy of oligodendroglial tumours: current developments. , 2000 .
[16] J. Cairncross,et al. Chemotherapy for oligodendroglioma. Progress report. , 1991, Archives of Neurology.
[17] M. Berger,et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas , 1994, Cancer.
[18] G S Bauman,et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. , 2000, International journal of radiation oncology, biology, physics.
[19] M. J. van den Bent,et al. Temozolomide chemotherapy in recurrent oligodendroglioma , 2001, Neurology.
[20] J. Cairncross,et al. Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.
[21] A. Allam,et al. Oligodendroglioma: an analysis of prognostic factors and treatment results. , 2000, American journal of clinical oncology.
[22] H. Korf,et al. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases , 1998, Acta Neuropathologica.
[23] D K Pearl,et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.
[24] B. Scheithauer,et al. Supratentorial gliomas: a comparative study by grade and histologic type , 1997, Journal of Neuro-Oncology.
[25] Pascale Varlet,et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria , 1997, Journal of Neuro-Oncology.
[26] G. Reifenberger,et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.
[27] A. von Deimling,et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. , 1999, Journal of neuropathology and experimental neurology.
[28] C. Daumas-Duport,et al. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases , 1997, Journal of Neuro-Oncology.
[29] B. Scheithauer,et al. Oligodendrogliomas: the Mayo Clinic experience. , 1992, Journal of neurosurgery.
[30] R A Betensky,et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] G. Bauman,et al. Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. , 2001, Seminars in radiation oncology.
[32] B. Scheithauer,et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.
[33] J. Cairncross,et al. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma , 1999, Neurology.
[34] M. Chamberlain,et al. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Fortuna,et al. Cerebral oligodendroglioma: prognostic factors and life history. , 1994, Neurosurgery.
[37] N. Bleehen,et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma , 1997, Cancer Chemotherapy and Pharmacology.
[38] J. Bruner,et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. , 1993, Neurosurgery.
[39] D. Louis,et al. Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.
[40] D. Louis,et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. , 2001, The American journal of pathology.
[41] B. Scheithauer,et al. The New WHO Classification of Brain Tumours , 1993, Brain pathology.
[42] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[43] G. Krol,et al. Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.
[44] K. Shin,et al. Radiation and chemotherapy improve outcome in oligodendroglioma. , 1997, International journal of radiation oncology, biology, physics.
[45] B. Scheithauer,et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] T. Buclin,et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration , 1998, Cancer Chemotherapy and Pharmacology.
[47] M. Berger,et al. The role of postoperative irradiation in the treatment of oligodendroglioma. , 1994, International journal of radiation oncology, biology, physics.
[48] J. Hahn,et al. Role of radiation therapy in the treatment of cerebral oligodendroglioma: an analysis of 57 cases and a literature review. , 1983, Neurosurgery.
[49] Jean-Yves Delattre,et al. OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.
[50] R A Betensky,et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. , 2001, Cancer research.
[51] R. McLendon,et al. Clinicopathologic correlations in the oligodendroglioma , 1987, Cancer.
[52] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[53] S. Green,et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.
[54] J. Kros,et al. Oligodendroglioma: the Rotterdam-Dijkzigt experience. , 1994, Neurosurgery.
[55] J. Dichgans,et al. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors , 2000, Journal of Neurology.
[56] A. Algra,et al. Oligoastrocytomas: a clinicopathological study of 52 cases , 1997, Journal of Neuro-Oncology.
[57] A. Paetau,et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients , 2001, Neurology.
[58] T. Cascino,et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Mitsutoshi Nakamura,et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas , 2002, Acta Neuropathologica.
[60] L. Deangelis,et al. Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.
[61] W. Simpson,et al. Oligodendroglioma. The princess margaret hospital experience (1958–1984) , 1993, Cancer.
[62] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[63] M. Nelen,et al. PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors. PTEN is only occasionally mutated in one of the two genetic subtypes. , 2000, Cancer genetics and cytogenetics.
[64] A. Chiò,et al. Prognostic Factors in Oligodendroglioma , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[65] K. Hoang-Xuan,et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression , 2001, Neurology.
[66] M Brada,et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] D. Louis,et al. Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.
[68] A. Brandes,et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. , 2001, Annals of Oncology.
[69] Edward Pan,et al. Glioblastoma Multiforme and Anaplastic Astrocytoma , 2003 .
[70] S P Langdon,et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.
[71] R. McLendon,et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. , 1999, The American journal of pathology.
[72] O. Chinot,et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] A. Karim,et al. Cognitive functions and quality of life in patients with low‐grade gliomas: The impact of radiotherapy , 1994, Annals of neurology.
[74] A. Twijnstra,et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.
[75] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[76] K. Wallner,et al. Treatment of oligodendrogliomas with or without postoperative irradiation. , 1988, Journal of neurosurgery.
[77] R. Soffietti,et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. , 1998, Neurosurgery.
[78] S. Schold,et al. Oligodendroglioma: An analysis of the value of radiation therapy , 1987 .
[79] D. Rowitch,et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[80] Rebecca A Betensky,et al. Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma” , 2002, Journal of neuropathology and experimental neurology.
[81] B. Scheithauer,et al. Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading , 2001, Journal of neuropathology and experimental neurology.